Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 58.48K shares.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 90.03K shares.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 118.84K shares, a 222.73% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was 36.82K shares, a 1372.92% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 162.39K shares, a 128.42% increase from fiscal 2023.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 71.09K shares, a 19.37% decline from fiscal 2022.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 88.17K shares, a 23.69% decline from fiscal 2021.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 115.55K shares, a 115.03% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 58.48K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | 90.03K shares 10-Q · filed 2026-05-07 | |
| 2024-12-31 | 118.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 162.39K shares 10-K · filed 2026-02-26 |
| 2023-12-31 | 36.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 71.09K shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 10.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | |
| 2022-12-31 | 2.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 88.17K shares 10-K · filed 2024-02-27 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 85.67K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 56.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 85.67K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 29.04K shares 10-Q · filed 2022-05-10 | 116.96K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 115.55K shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | |
| 2021-06-30 | 87.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | |
| 2021-03-31 | 27.63K shares 10-Q · filed 2021-05-07 | |
| 2020-12-31 | 53.74K shares 10-K · filed 2023-02-23 | |
| 2019-12-31 | 76.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 142.78K shares 10-K · filed 2022-02-24 |
| 2019-09-30 | 64.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | |
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 59.45K shares 10-K · filed 2021-02-25 |
| 2018-09-30 | 12.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | 59.45K shares derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | 46.70K shares derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | 46.70K shares 10-Q · filed 2018-05-08 | 48.08K shares derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | 36.74K shares 10-K · filed 2020-02-25 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | 62.73K shares derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | 1.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | 83.72K shares derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | 35.36K shares 10-Q · filed 2017-05-09 | |
| 2016-12-31 | 25.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | 51.98K shares 10-K · filed 2019-03-18 |
| 2016-09-30 | 20.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |